Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low toxicity and significant anticancer activity in vitro and in vivo. It shows greater potency than BA at... It shows greater potency than BA at inducing malignant cell differentiation and tumor growth inhibition and has demonstrated more favorable toxicological, pharmacological, and pharmaceutical properties than BA in preclinical studies.
- Mechanism
- Curator reviewed
Pivaloyloxymethyl butyrate is a histone deacetylase inhibitor analog of butyric acid that causes apoptosis of cancer cells through signaling cellular differentiation. It is rapidly and extensively transported intracellularly because of its high lipophilicity, where it undergoes esterase-mediated hydrolysis to form pivalic acid, formaldehyde, and BA.
- Primary indication
- Investigated for use/treatment in liver cancer, lung cancer, melanoma, and leukemia (lymphoid).Curator reviewed
- Formula / weight
- C10H18O4 · 202.25 g/mol (avg)
- Also known as
- Pivaloyloxymethyl butyrate · Pivaloyloxymethylbutyrate · Pivanex
Resolves to
GYKLFBYWXZYSOW-UHFFFAOYSA-NSMILESCCCC(=O)OCOC(=O)C(C)(C)CWhat you can answer from here — as of April 02, 2025
Which drugs share a target with AN-9, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account